Terumo BCT

Cincinnati, Ohio

Oncologysmall moleculeGrant-only

Compare Sign in to watch

What changed

NIH R01 · $0.7M · Concomitant Inhibition of VAV3 and ERa to Treat High-Risk B-ALL

7w agoNew grantMay 26, 2026Source filing (opens the source filing in a new tab)

Momentum

60no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $684k · non-dilutive
Jun 1, 2026
CINCINNATI CHILDRENS HOSP MED CTR · PI NASSAR, NICOLAS · NCI · award ends May 31, 2031 · Concomitant Inhibition of VAV3 and ERa to Treat High-Risk B-ALL
NIH RePORTER · NIH RePORTER 11364664 (opens the source filing in a new tab)
Trial
NA registered
Nov 11, 2021
Device Validation of In-vivo Performance · COMPLETED · sponsor: Terumo BCT · An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System
ClinicalTrials.gov · NCT05239455 (opens the source filing in a new tab)
Grant
R01 · $867k · non-dilutive
Jul 1, 2020
DANA-FARBER CANCER INST · PI CANCELAS, JOSE A. · NIDDK · award ends Feb 28, 2030 · Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
NIH RePORTER · NIH RePORTER 11363848 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.22no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.7M · Concomitant Inhibition of VAV3 and ERa to Treat High-Risk B-ALL
7w agoNew grantSource (opens the source filing in a new tab)
NIH R01 · $0.9M · Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
2mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System
Jan 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $684k · non-dilutive

NA registered

R01 · $867k · non-dilutive